NURTEC® ODT Principal Display Panel (rimegepant) | Pfizer Medical Information

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Carton

NDC 72618-3000-2
NURTEC® ODT
(rimegepant)
orally disintegrating tablets

75 mg PER ORALLY DISINTEGRATING TABLET (ODT)

This package contains 8 ODTs.
Rx only

Pfizer
Distributed by
Pfizer Labs
Division of Pfizer Inc.
New York, NY 10017

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Carton

PRINCIPAL DISPLAY PANEL - 75 mg NURTEC ODT Blister Pack

PEEL HERE
NURTEC® ODT
(rimegepant) orally
disintegrating tablets
75 mg
LOT
EXP.YYYY/MM
Pfizer Labs
Rx only

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Carton SAMPLE

NDC 72618-3001-2
Contains 4 of NDC 72618-3001-1

PROFESSIONAL SAMPLE -
NOT FOR SALE

Rx only

NURTEC® ODT
(rimegepant)
orally disintegrating tablets

75 mg PER ORALLY DISINTEGRATING TABLET

This carton contains 4 blister packs containing 2 orally disintegrating tablets (ODT) each for patient sampling.
Contents in this package are NOT for individual sale. Recommended Dosage: See prescribing information.

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Carton SAMPLE

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Dosepak SAMPLE

NDC 72618-3001-1

PROFESSIONAL SAMPLE -
NOT FOR SALE

NURTEC® ODT
(rimegepant)
orally disintegrating tablets

75 mg PER ORALLY DISINTEGRATING TABLET (ODT)

This package contains 2 ODTs.

Rx only

PRINCIPAL DISPLAY PANEL - 75 mg Tablet Blister Pack Dosepak SAMPLE

PRINCIPAL DISPLAY PANEL - 75 mg NURTEC ODT Blister Pack SAMPLE

PEEL HERE
NURTEC® ODT
(rimegepant) orally
disintegrating tablets
75 mg
PROFESSIONAL SAMPLE -
NOT FOR SALE
LOT
Rx only
EXP. YYYY/MM
Pfizer Labs

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NURTEC® ODT Quick Finder

Pfizer samples (for eligible HCPs)

Requests for samples of prescription medications can be made by contacting Pfizer for Professionals at 1-800-505-4426 or by visiting the PfizerPro website www.pfizerpro.com.
Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All